Table 3.
Treatment Characteristics
| All Patients (n=155) |
TARE_alone (n=55) |
TARE_sorafenib (n=74) |
TARE_alternative (n=26) |
|
|---|---|---|---|---|
| Treatment before TARE, n (%) | ||||
| None | 80 (51.6) | 30 (54.5) | 44 (59.5) | 6 (23.1) |
| Locala | 50 (32.3) | 17 (30.9) | 26 (35.1) | 7 (26.9) |
| Systemicb | 25 (16.1) | 8 (14.5) | 4 (5.4) | 13 (50) |
| TAREc | ||||
| Median LSF, % (range) | 6.0 (1.1–30.4) | 4.6 (1.1–26.4) | 6.3 (1.2–30.4) | 6.6 (2.0–20.8) |
| Median lung dose, Gy (range) | 8.5 (0.5–49.0) | 4.7 (0.5–29.2) | 11.5 (0.6–49.0) | 12.7 (2.0–29.2) |
| Median mean absorbed dose to treated liver volume, Gy (range) | 110 (80–135) | 110 (80–135) | 110 (80–135) | 110 (80–135) |
| Median interval between 99mTc MAA and TARE, days (range) | 20 (0–78) | 21 (0–78) | 18 (0–44) | 21 (10–34) |
| Median administered activity (GBqd), range | 2.9 (0.5–8.1) | 1.9 (0.5–5.8) | 3.0 (0.6–8.1) | 2.6 (0.8–6.3) |
| TARE procedures, n (%) | ||||
| 1 | 138 (89) | 47 (85.5) | 66 (89.2) | 25 (96.2) |
| 2 | 14 (9) | 7 (12.7) | 7 (9.5) | 0 |
| 3 | 3 (1.9) | 1 (1.8) | 1 (1.4) | 1 (3.8) |
| Approach | ||||
| Whole liver | 40 (23.7) | 11 (20) | 21 (28.4) | 5 (19.2) |
| Lobar | 124 (73.4) | 41 (74.5) | 51 (68.9) | 21 (80.8) |
| Segmental | 5 (3.0) | 3 (5.5) | 2 (2.7) | 0 |
| Treatment after TARE, n (%) | ||||
| Nonee | 50 (32.3) | 25 (45.5) | 21 (28.4) | 4 (15.4) |
| Best supportive care | 36 (23.2) | 8 (14.5) | 15 (20.3) | 13 (50) |
| Local | 22 (14.2) | 12 (21.8) | 8 (10.8) | 2 (7.7) |
| Systemic | 47 (30.3) | 10 (18.2) | 30 (40.5) | 7 (26.9) |
Notes: aIncluded surgical resection, transarterial embolization (TAE), transarterial chemoembolization (TACE), TARE, radiofrequency ablation (RFA), and microwave ablation (MWA). bIncluded chemotherapy, targeted therapy and immunotherapy. cFirst TARE only. dGigabecquerel. eNo treatment because of no progression.